Sir,

The authors have done a laudable work in re-addressing the issue of fine needle aspiration cytology (FNAC) role in extra-adrenal paraganglioma (EAP) in their article.\[[@ref1]\] I have few comments to put forth in this regard. First, paraganglioma and pheochromocytoma are clinically, biochemically, and pathologically similar, except for unique phenyl-ethanolamine *N*-methyl transferase (PNMT) expression and epinephrine synthesis in the former.\[[@ref2]\] Second, the diagnosis of catecholamine secreting tumors (CST) relies on demonstration of elevated plasma/urinary metanephrines,\[[@ref3]\] and not preoperative cytology. FNAC of these tumors are highly non-specific due to significant overlap with other pathologies and degenerative changes such as cystic, hemorrhagic, and necrotic changes.\[[@ref4]\]

Third, the statement that "FNAC is not necessarily contraindicated" for the diagnosis of paraganglioma, in my view is fallacious. Evidence suggests that FNAC in a known case of CST is contraindicated and indeed it has to be ruled out before contemplating FNAC.\[[@ref3]\] Moreover, FNAC apart from the risk of hemorrhage can lead to hypertensive crises, which can be fatal if not dealt with or anticipated.\[[@ref5]\] Fourth, the phenomenon of capsular breach and metastatic spread after FNAC of EAP is possible, in view of high rate of malignancy in EAP.\[[@ref5]\] Finally, diagnosis of EAP on FNAC is more incidental and not an intentional event. In view of above facts, FNAC has a limited role of suggesting a neuro-endocrine tumor in an undiagnosed and unsuspected retroperitoneal mass and not recommended in routine practice.
